Simcere Pharmaceutical Group Limited
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative drugs, with a diversified portfolio targeting oncology, central nervous system disorders, autoimmune diseases, cardiovascular conditions, anti-infection therapies, and other therapeutic areas. Founded in 1995 and headquartered at No. 699-18 Xuanwu Avenue, Nanjing, China, the company operates primarily in China through four R&D centers in Shanghai, Nanjing, Beijing, and Boston, and maintains a broad commercial presence covering class III hospitals and other medical institutions nationwide. Its core products include proprietary innovative drugs such as Endostar (a recombinant human endostatin for oncology), Iremod (for autoimmune diseases), Bicun (a CNS drug), Sinofuan, Zailin, Antine, Yeqing, Jiebaishu, and Newanti (first-to-launch or first-in-class offerings); generic pharmaceuticals like Jepaso, Jiebaili, and Yingtaiqing (diclofenac sodium sustained-release capsules); and third-party distributed products including Faneng (alfacalcidol soft capsules) and Yineng (lentinan injection), alongside over 50 branded pharmaceuticals spanning prescription and over-the-counter categories, with additional involvement in pharmaceutical ingredients production and promotion services for third-party drugs sold via medical institutions. The company leverages subsidiaries like Simcere Zaiming, an oncology-focused biopharma established in 2023, to advance specialized pipelines including 15 clinical-stage assets and launched products such as COSELA, Enweida, Endostar, and Enlituo. Recent developments include an exclusive licensing agreement with Vigonvita Life Sciences announced on December 3, 2025, for undisclosed assets; a January 2025 partnership between Simcere Zaiming and AbbVie to develop SIM0500, a trispecific T-cell engager for relapsed or refractory multiple myeloma in phase I trials, potentially worth up to $1.055 billion; a June 2025 strategic collaboration with NextCure for SIM0505, a CDH6-targeted antibody-drug conjugate in phase I in China with U.S. trials planned, valued up to $745 million; and a November 2025 announcement of a regulatory T-cell preferential IL-2 mutant Fc fusion protein, alongside strategic regional licensing with Vivoryon Therapeutics for SIM0801 in Greater China and collaboration with Guangzhou Fermion Technology for FZ002-037 pain treatment.
Company News
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
Boehringer Ingelheim en Simcere werken samen aan een dubbeldoelgerichte antilichaambehandeling om tegemoet te komen aan onvervulde behoeften bij inflammatoire darmziekten
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Ipsen élargit son portefeuille de produits en développement précoce avec un conjugué anticorps-médicament innovant développé par Simcere Zaiming
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate